STUDYING THE EFFECTIVENESS OF MONOCLONAL ANTIBODIES AGAINST CORONAVIRUS INFECTION
Keywords:
Monoclonal antibodies, Coronavirus, SARS-CoV-2Abstract
Monoclonal antibodies (mAbs) have emerged as a promising therapeutic option for the prevention and treatment of coronavirus infections, particularly COVID19 caused by the SARS-CoV-2 virus. These laboratory-made proteins target specific components of the virus, preventing viral entry into human cells and subsequent replication. Clinical trials and real-world evidence have demonstrated the efficacy of monoclonal antibodies in reducing the severity of COVID-19 symptoms, decreasing the risk of hospitalization and death, and providing immediate protection against the virus through passive immunization.
References
M. Dougan, A. Nirula, M. Azizad, et al. Bamlanivimab plus etesevimab in mild or moderate Covid-19 N. Engl. J. Med., 385 (July 14 2021), pp. 1382-1392, 10.1056/NEJMoa2102685
D.M. Weinreich, S. Sivapalasingam, T. Norton, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 N. Engl. J. Med., 384 (January 21 2021), pp. 238-251, 10.1056/NEJMoa2035002
J.R. Bariola, E.K. McCreary, R.J. Wadas, et al. Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among nonhospitalized adults with severe acute respiratory syndrome Coronavirus 2 infection Open Forum Infect Dis, 8 (July 2021), 10.1093/ofid/ofab254 ofab254
P. Chen, A. Nirula, B. Heller, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 N. Engl. J. Med., 384 (January 21 2021), pp. 229-237, 10.1056/NEJMoa2029849
S. Jiang, C. Hillyer, L. Du Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses Trends Immunol., 41 (May 2020), pp. 355-359, 10.1016/j.it.2020.03.007
D.M. Weinreich, S. Sivapalasingam, T. Norton, et al. REGEN-COV antibody cocktail clinical outcomes study in Covid-19 outpatients medRxiv (2021), 10.1101/2021.05.19.21257469 2021.05.19.21257469
U.S. Food and Drug Administration Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab https://www.fda.gov/media/145802/download (November 9, 2020) (accessed July 20, 2021)
U.S. Food and Drug Administration Fact sheet for Health Care Providers Emergency Use Authorization (EUA) of Bamlanivimab
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
